We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam Reports Positive Phase III Results on Lumasarin
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced positive phase III results from the ILLUMINATE-A study on its RNAi candidate, lumasiran in development for the treatment of primary hyperoxaluria type 1 (PH1).. Data from the study showed that PH1 patients treated with lumasiran met the primary efficacy endpoint of percent change from baseline, relative to placebo. The study also achieved statistically significant results for all six tested secondary endpoints, including the proportion of patients achieving a near-normalization or normalization of urinary oxalate.
Lumasiran achieved the ILLUMINATE-A primary endpoint with a 53.5% mean reduction in urinary oxalate relative to placebo and showed a 65.4% mean reduction in urinary oxalate relative to baseline. In the study, 84% of patients on lumasiran achieved normal or near-normal levels of urinary oxalate and more than half of patients reached normalization compared with zero percent in the placebo group.
The drug demonstrated an encouraging safety and tolerability profile with no serious or severe adverse events (AEs) and with mild injection site reactions as the most common drug-related AE.
The substantial and sustained reductions in urinary and plasma oxalate demonstrated that lumasiran addresses the underlying pathophysiology of PH1 by reducing the production of the toxic metabolite responsible for the clinical manifestations of this serious and progressive disease.
Based on these results, Alnylam has filed a new drug application (NDA) with the FDA. The FDA has granted a Priority Review to the NDA with an action date of Dec 3, 2020.
In addition, the marketing authorization application (MAA) for lumasiran has received an accelerated assessment from the European Medicines Agency (EMA).
Shares of Alnylam have gained 10.8% year to date compared with the industry’s growth of 6.9%.
Meanwhile, the company is also evaluating several other candidates. A few significant ones include vutrisiran, inclisiran and fitusiran. The HELIOS-A phase III study is evaluating vutrisiran for the treatment of hATTR amyloidosis with polyneuropathy. Another phase III study, HELIOS-B, is evaluating the candidate in hereditary and wild-type ATTR amyloidosis with cardiomyopathy. The company is developing fitusiran in partnership with Sanofi (SNY - Free Report) in the ATLAS phase III program for the treatment of hemophilia A or B with and without inhibitors. Alnylamand partner Novartis’ (NVS - Free Report) inclisiran is under review in the United States and Europe for treating heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.
Alnylam has a collaboration agreement with Regeneron Pharmaceuticals (REGN - Free Report) to discover, develop and commercialize new RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the liver, eye and central nervous system.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Alnylam Reports Positive Phase III Results on Lumasarin
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced positive phase III results from the ILLUMINATE-A study on its RNAi candidate, lumasiran in development for the treatment of primary hyperoxaluria type 1 (PH1).. Data from the study showed that PH1 patients treated with lumasiran met the primary efficacy endpoint of percent change from baseline, relative to placebo. The study also achieved statistically significant results for all six tested secondary endpoints, including the proportion of patients achieving a near-normalization or normalization of urinary oxalate.
Lumasiran achieved the ILLUMINATE-A primary endpoint with a 53.5% mean reduction in urinary oxalate relative to placebo and showed a 65.4% mean reduction in urinary oxalate relative to baseline. In the study, 84% of patients on lumasiran achieved normal or near-normal levels of urinary oxalate and more than half of patients reached normalization compared with zero percent in the placebo group.
The drug demonstrated an encouraging safety and tolerability profile with no serious or severe adverse events (AEs) and with mild injection site reactions as the most common drug-related AE.
The substantial and sustained reductions in urinary and plasma oxalate demonstrated that lumasiran addresses the underlying pathophysiology of PH1 by reducing the production of the toxic metabolite responsible for the clinical manifestations of this serious and progressive disease.
Based on these results, Alnylam has filed a new drug application (NDA) with the FDA. The FDA has granted a Priority Review to the NDA with an action date of Dec 3, 2020.
In addition, the marketing authorization application (MAA) for lumasiran has received an accelerated assessment from the European Medicines Agency (EMA).
Shares of Alnylam have gained 10.8% year to date compared with the industry’s growth of 6.9%.
Meanwhile, the company is also evaluating several other candidates. A few significant ones include vutrisiran, inclisiran and fitusiran. The HELIOS-A phase III study is evaluating vutrisiran for the treatment of hATTR amyloidosis with polyneuropathy. Another phase III study, HELIOS-B, is evaluating the candidate in hereditary and wild-type ATTR amyloidosis with cardiomyopathy. The company is developing fitusiran in partnership with Sanofi (SNY - Free Report) in the ATLAS phase III program for the treatment of hemophilia A or B with and without inhibitors. Alnylamand partner Novartis’ (NVS - Free Report) inclisiran is under review in the United States and Europe for treating heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.
Alnylam has a collaboration agreement with Regeneron Pharmaceuticals (REGN - Free Report) to discover, develop and commercialize new RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the liver, eye and central nervous system.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote
Zacks Rank
Alnylam is a Zacks Rank #3 (Hold) stock, currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>